Palavras-chave
Therapeutics
Adrenal Cortex Hormones
Antiviral Agent
Monoclonal Antibodies
Immunologic Factors
Como Citar
Resumo
Background: The COVID-19 pandemic has evolved rapidly, causing significant global mortality and straining healthcare systems. While new therapeutic strategies are continually emerging, several repurposed drugs have been evaluated for their potential efficacy against SARS-CoV-2. Recent advancements in treatment protocols and the emergence of new variants necessitate an updated analysis of therapeutic options. Objective: This review critically analyzes the role of repurposed drugs, including chloroquine, ivermectin, and nitazoxanide, as well as corticosteroids, immunomodulators, and novel antiviral strategies for the treatment of COVID-19 in Brazil. The discussion incorporates emerging evidence from clinical trials and the latest research on treatment responses to new variants of the virus. Methodology: This study synthesizes evidence from clinical trials, systematic reviews, and meta-analyses available in databases such as PUBMED, BVS/BIREME, Web of Science, Science Direct, CAPES Portal, Cochrane Library, and PROSPERO. Studies evaluating the efficacy and safety of repurposed drugs and novel interventions in different phases of the disease were included. Results: While chloroquine, ivermectin, and nitazoxanide initially showed in vitro antiviral activity, randomized controlled trials have not demonstrated significant clinical benefits. However, dexamethasone and other corticosteroids remain the cornerstone for managing severe COVID-19 cases with respiratory failure. Additionally, monoclonal antibodies, antiviral drugs like remdesivir and molnupiravir, and immunomodulatory therapies, such as tocilizumab and baricitinib, have emerged as effective options, particularly against severe disease forms caused by new variants. Conclusion: Although initial enthusiasm for repurposed antiparasitic drugs has waned due to lack of robust evidence, corticosteroids, targeted antiviral therapies, and immunomodulators have demonstrated efficacy, especially in severe cases. Ongoing research is essential to refine treatment protocols and optimize therapeutic strategies for emerging SARS-CoV-2 variants.
Referências
Beigel JH, Tomashek KM, Dodd LE, et al. Remdesivir para o tratamento da Covid-19 — Relatório final. N Engl J Med. 2020;383(19):1813-1826.
Gandhi RT. O desafio multidimensional do tratamento da COVID-19: Remdesivir, corticosteroides e além. Clin Infect Dis. 2022;74(3):469-471.
Gottlieb RL, Vaca CE, Paredes R, et al. Remdesivir precoce para prevenir a progressão para Covid-19 grave em pacientes ambulatoriais. N Engl J Med. 2021;386(4):305-315.
Johnson NP, Mueller J. Atualizando as contas: mortalidade global da pandemia de gripe "espanhola" de 1918-1920. Bull Hist Med. 2002;76(1):105-115.
Marconi VC, Ramanan AV, de Bono S, et al. Eficácia e segurança do baricitinibe para o tratamento de adultos hospitalizados com COVID-19 (COV-BARRIER): um estudo randomizado, duplo-cego e controlado por placebo. Lancet Respir Med. 2021;9(12):1407-1418.
Martineau AR, Forouhi NG. Vitamina D para COVID-19: um caso a ser respondido? Lancet Diabetes Endocrinol. 2021;9(2):81-83.
RECOVERY Collaborative Group. Dexametasona em pacientes hospitalizados com Covid-19. N Engl J Med. 2020;384(8):693-704.
Consórcio de Ensaios Solidários da OMS. Medicamentos antivirais reaproveitados para Covid-19 — Resultados provisórios do ensaio de solidariedade da OMS. N Engl J Med. 2021;384(6):497-511
Este trabalho está licenciado sob uma licença Creative Commons Attribution 4.0 International License.
Copyright (c) 2025 Marvin Gonçalves Duarte, Gracielle Radja Rodrigues de Lima, Juliana Perez Leyva Ataíde, Letícia Almeida Guedes de Lima, Ana Carolina Bastos do Rêgo, Rodolfo Scavuzzi Carneiro da Cunha, Eudoro de Queiroz Marques Filho, Rosana Maria Coelho Travassos, Ailton Coelho de Ataíde Filho, Luciano Barreto Silva